Prellis Biologics
Medical AI · Drug Discovery
$47.3Mtotal raised · 5 rounds on record
$17Mlatest round · Series B · Jun 2022 · 4 yr ago
4backers · Plug and Play, SOSV
2017founded
Overview
At Prellis Biologics, we harness AI and immune diversity to advance next-gen medicines. Discover our EXIS™ platform and bioprinting technology.
Key facts
These are the key facts about Prellis Biologics on Alion as of Nov 13, 2026. Prellis Biologics is headquartered in Berkeley, United States. It was founded in 2017. It has raised $47.3M in 5 funding rounds. The latest round is Series B of $17M, announced in 2022.
- Headquarters
- Berkeley, United StatesAlion company profile, updated Sep 29, 2026
- Founded
- 2017Alion company profile, updated Sep 29, 2026
- Total raised
- $47.3MSum of 5 equity rounds Alion knows
- Latest round
- Series B · $17M · Jun 22, 2022SEC Form D filing · sec.gov
- Visa sponsorship, United States
- 2 ▲ 100% · H-1B filings in 12 monthsUS Department of Labor · latest filing Apr 27, 2026
Funding and backers
Total raised
$47.3M
5 rounds on record
Latest round
$17M
Series B · Jun 2022 · 4 yr ago
Backers
4
Plug and Play, SOSV
The money's age
Long since its last round
52 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jul 6, 2022
Board appointment Sean O'Sullivan, Director · SEC Form D
Jun 22, 2022
Raised a round Series B $17M · SEC Form D
Jul 14, 2021
Board appointment Alex Morgan, Director · SEC Form D
Jul 1, 2021
Raised a round Venture round $19.3M · SEC Form D
Jul 29, 2019
Raised a round Series A $8.7M
Jan 22, 2018
Raised a round Convertible Note $460k · SEC Form D
Jun 23, 2017
Raised a round Venture round $1.8M · SEC Form D
2017
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series B | Jun 2022 | $17M | — | SEC Form D |
| Venture round | Jul 2021 | $19.3M | — | SEC Form D |
| Series A | Jul 2019 | $8.7M | — | businesswire.com |
| Convertible Note | Jan 2018 | $460k | — | SEC Form D |
| Venture round | Jun 2017 | $1.8M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Prellis Biologics, Inc | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Noelle MullinExecutive Officer, DirectorSEC Form D
Melanie MatheuExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Stemnovate page on drug discovery. The platforms provide solutions for next gen liver, heart and brain cell modelling.
Invenra delivers high-quality antibody discovery and engineering solutions, including monoclonal, bispecific, and trispecific antibodies…
Accelerate intelligent drug development with DVLP. We harness collaborative AI to move molecules to commercialized intelligent drugs with…
Drug discovery at the resolution of biology. Using the power of the transcriptome to discover revolutionary medicines.
We partner with top biopharmaceutical companies and research institutions to discover and advance novel therapeutics.
Leading the advancement of biologics for targeted immune regulation & restoration.
Visa sponsorship
2 ▲ 100%
H-1B filings in 12 months
$123k
Median offered salary
0
Open roles in United States
Who they sponsor
Bioengineers and biomedical engineers
1
Other biological scientists
1
In the register as Prellis Biologics Inc., Berkeley, CA
Other sponsors in the same field
Genentech 
Generate:Biomedicines 
Alloy Therapeutics
Alert me
US Department of Labor · latest filing Apr 27, 2026 · Visa details by country
People
Noelle Mullin
Executive Officer, Director
Melanie Matheu
Executive Officer, Director
Arvind Gupta
Director
Rohit Sharma
Director
Michael Marks
Director
Shaun Holt
Director
Alex Morgan
Director
Sean O'Sullivan
Director
Lei Meng
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Future VenturesVia a fund
Celesta CapitalVia a fund
SOSVVia a fund
780 portfolio companies
Plug and PlayVia a fund
2741 portfolio companies
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
Shared investors
News
Prellis Biologics Enters Multi-Target Drug Discovery & Development Collaboration with Lilly to Advance Human Antibody Therapeutics
/PRNewswire/ -- Prellis Biologics, Inc., a biotechnology company innovating human antibody discovery through organoid & artificial intelligence enabled...
Read more
Report
Human Tissue Engineering Company Prellis Biologics Raises $8.7 Million Series A Round; Announces First Animal Transplant of Its 3D-Printed Tissue
Read more
Report
View via Businesswire.com
"Prellis Bio's differentiated LNOs generated by holographic two-photon 3D printing technology have the potential to transform the landscape of antibody discovery and preclinical assessment of biologics," said Lei Meng, Senior Therapeutics Analyst of Avidi
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Berkeley
United States
HQ
Prellis Biologics
999 Anthony St, Berkeley, 94710
How to cite this page
Alion, "Prellis Biologics: key facts", as of Nov 13, 2026. https://alion.io/company/prellisbio
These figures are published under a free licence. You may reuse them, including commercially, as long as you credit Alion and link back to this page. CC BY-SA 4.0